- Cluster Headache Characteristics and the Severity of Obstructive Sleep Apnea: Insights from Polysomnography Analysis
-
Yooha Hong, Mi-Kyoung Kang, Min Kyung Chu, Soo-Jin Cho, Hee-Jin Im
-
Headache Pain Res. 2024;25(1):63-71. Published online April 16, 2024
-
DOI: https://doi.org/10.62087/hpr.2024.0001
-
-
 Abstract
 PDF
- Purpose: Cluster headache (CH) is characterized by circadian rhythmicity of the attacks, and it is known to respond exceptionally well to oxygen therapy. Furthermore, obstructive sleep apnea (OSA) frequently co-occurs with CH, and both conditions may be parallel outcomes of hypothalamic dysfunction rather than being causally related. The aim of this study was to analyze the association between CH characteristics and polysomnographic factors stratified by the severity of OSA in patients diagnosed with CH and OSA.
Methods
We retrospectively analyzed the data of OSA patients with CH who were enrolled in the Korean Cluster Headache Registry and underwent polysomnography due to clinical suspicion of OSA. Basic demographic data, headache-related parameters, and polysomnographic parameters were analyzed according to the severity of OSA (apnea-hypopnea index: <15 or ≥15 per hour).
Results
Twelve CH patients with OSA were evaluated. The onset age of CH was higher (38.5 years vs. 19.0 years, p=0.010), and the maximal duration of cluster bouts was longer (156.5 days vs. 47.0 days, p=0.037) in the moderate-to-severe OSA group than in the mild OSA group. Unlike other polysomnographic parameters, the apnea-hypopnea index and respiratory arousal index during rapid eye movement (REM) sleep were comparable across different OSA severity levels.
Conclusion
The onset age and duration of cluster bouts were associated with the severity of OSA in CH patients. Additionally, the relatively high susceptibility to hypoxia during REM sleep in patients with mild OSA implies that interventions may be potentially advantageous, even in CH patients with mild OSA.
- Treatment Strategies of Medication Overuse Headache
-
Mi-Kyoung Kang, Jong-Hee Sohn
-
Korean J Headache. 2023;24(2):33-38. Published online December 31, 2023
-
-
-
Abstract
PDF
- Medication overuse headache (MOH) is a common secondary headache disorder in which chronic headaches develop or worsen due to frequent and excessive intake of medications used for acute headache treatment. While the concept of MOH is widely recognized among headache specialists, ongoing debates exist regarding its causes, diagnostic criteria, and treatment strategies. Treating MOH has traditionally been challenging, and there is currently no universal consensus on how to effectively manage patients with MOH. Furthermore, a specific treatment approach based on well-powered randomized trials is still lacking. The treatment strategy for MOH typically involves several steps: patient education and counseling, withdrawal of overused medications, preventive drug therapy, and non-pharmacological prevention. It is recommended that all patients discontinue the overused medication, which can be carried out on an outpatient or inpatient basis. Additionally, topiramate, Botox, and anti-calcitonin gene-related peptide monoclonal antibodies have shown potential in reducing headache and migraine frequency, as well as acute drug consumption, even without active drug withdrawal. However, many aspects of MOH management require further investigation through properly designed and adequately powered randomized controlled trials.
- Diagnosis and Treatment of Hemicrania Continua, Paroxysmal Hemicrania, Short-lasting Unilateral Neuralgiform Headache Attacks
-
Sang-Hwa Lee, Mi-Kyoung Kang, Soo-Jin Cho
-
Korean J Headache. 2023;24(2):39-44. Published online December 31, 2023
-
-
-
Abstract
PDF
- Chronic paroxysmal hemicrania, short-lasting unilateral neuralgiform headache attacks, and hemicrania continua are rare headache disorders characterized by severe unilateral headache accompanied by ipsilateral autonomic symptoms. Accurate diagnosis and specific treatment approaches for these conditions are crucial for appropriate management. This article covers the clinical features, diagnostic criteria, and treatment strategies of each disorder, aiming to differentiate them from other major headaches and provide targeted treatment strategies to improve patient outcomes.
- Update on Treatment of Giant Cell Arteritis
-
Mi-Kyoung Kang, Yoo Hwan Kim, Kyeong Min Son, Soo-Jin Cho , Jiyoung Kim, Jong-Hee Sohn, On behalf of the Hallym Headache Research Society
-
Published online December 31, 2022
-
-
-
Abstract
PDF
- 거대세포동맥염의 최신 지견
- A Intractable Headache Caused by Increased Intracranial Pressure after Surgical Resection of the Spinal Arachnoid Cyst
-
Mi-Kyoung Kang, Han Beet Kim, Il Choi, Soo-Jin Cho
-
Published online December 31, 2022
-
-
-
Abstract
PDF
- 척추 지주막낭의 수술적 제거 후 발생한 두개내압 상승에 기인한 난치성 두통
- Giant Cell Arteritis Diagnosed by HALO Score of Ultrasonography and Fat-saturated Contrast Enhanced Vessel Wall Magnetic Resonance Imaging
-
Han-Beet Kim, Mi-Kyoung Kang, Min-Jun Song, Ki-Won Nam, Sang Won Jo, Ki-Han Kwon, Soo-Jin Cho
-
Published online December 31, 2022
-
-
-
Abstract
PDF
- 초음파 검사의 달무리 징후와 지방포화혈관벽조영증강자기 공명영상으로 진단된 거대세포동맥염
|
KHS
